Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines

Experimental Neurology

Volumn 162, Issue 1, 2000, Pages 37-50

  Trimmer, Patricia A ^a   Swerdlow, Russell H ^a   Parks, Janice K ^a   Keeney, Paula ^a   Bennett Jr , James P ^a   Miller, Scott W ^b   Davis, Robert E ^b   Parker Jr , W Davis ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b Migenix Inc   (United States)

Author keywords

Alzheimer's disease; Cybrid; Electron microscopy; Mitochondria; Mitochondrial inclusions; Neuroblastoma; Parkinson's disease

Indexed keywords

MITOCHONDRIAL DNA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; HUMAN; HUMAN CELL; MALE; MEMBRANE POTENTIAL; NEUROBLASTOMA CELL; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATORY CHAIN;

EID: 0034102780     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7333     Document Type: Article

References (70)

1. Anglade P., Mouatt-Prigent A., Agid Y. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration. 5:1996;121-128.
2. Anglade P., Vyas S., Hirsch E. C., Agid Y. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol. Histopathol. 12:1997;603-610.
3. Anglade P., Vyas S., Javoy-Agrid F., Herrero M. T., Michel P. P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E. C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12:1997;25-31.
4. Askanas V., McFerrin J., Baque S., Alvarez R. B., Sarkozi E., Engel W. K. Transfer of β-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc. Natl. Acad. Sci. USA. 93:1996;1314-1319.
5. Baloyannis S. J. Mitochondrial alterations in Alzheimer's disease. Neurobiol. Aging. 19:1998;S241.
6. Bernardi P., Petronilli V. The permeability transition pore as a mitochondrial calcium release channel: A critical appraisal. J. Bioenerg. Biomemb. 28:1996;131-138.
7. Bowling A. C., Beal M. F. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci. 56:1995;1151-1171.
8. Cassarino D. S., Fall C. P., Swerdlow R. H., Smith T. S., Halvorsen E. M., Miller S. M., Parks J. P., Parker W. D. Jr., Bennett J. P. Jr. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta. 1362:1997;77-86.
9. Chandrasekaran K., Giordano T., Brady D. R., Stoll J., Martin L. J., Rapoport S. I. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Mol. Brain Res. 24:1994;336-340.
10. Christie-Pope B. C., Burns R. S., Whetsell W. O. Ultrastructural alterations induced by 1-methyl-4-phenylpyridinium (MPP+) in canine substantia nigra and rat mesencephalon in vitro. Exp. Neurol. 104:1989;235-240.
11. Cossarizza A., Ceccarelli D., Masini A. Functional heterogeneity of an isolated mitochondrial population revealed by cytoflurometric analysis at the single organelle level. Exp. Cell Res. 222:1996;84-94.
12. Davis R. E., Miller S., Herrnstadt C., Ghosh S. S., Fahy E., Shinobu L. A., Galasko D., Thal L. J., Beal M. F., Howell N., Davis Parker J. W. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 94:1997;4526-4531.
13. Dunn W. A. J. Studies on the mechanism of autophagy: Maturation of the autophagic vacuole. J. Cell Biol. 110:1990;1935-1945.
14. Ekeren G. J. v., Stadhouders A. M., Egberink G. J. M., Sengers R. C. A., Daniels P., Kubat K. Hereditary mitochondrial hypertrophic cardiomyopathy with mitochondrial myopathy of skeletal muscle, congenital cataract and lactic acidosis. Virch. Arch. A. 412:1987;47-52.
15. Eppenberger-Eberhardt M., Riesinger I., Messerli M., Schwarb P., Muller M., Eppenberger H. M., Wallimann T. Adult rat cardiomyocytes cultured in creatine-deficient medium display large mitochondria with paracrystalline inclusions, enriched for creatine kinase. J. Cell Biol. 113:1991;289-302.
16. Farrants G. W., Hovmoller S., Stadhouders D. M. Two types of mitochondrial crystals in diseased human skeletal muscle fibers. Muscle Nerve. 11:1988;45-55.
17. Forno L. S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55:1996;259-272.
18. Forno L. S., Norville R. L. Ultrastructure of Lewy bodies in the stellate ganglion. Acta Neuropathol. 34:1976;183-197.
19. Graeber M. B., Grasbon-Frodl E., Eitzen U. V., Kossel S. Neurodegeneration and aging: Role of the second genome. J. Neurosci. Res. 52:1998;1-6.
20. Gu M., Cooper J. M., Taanman J. W., Schapira A. H. V. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann. Neurol. 44:1998;177-186.
21. Handran S. D., Werth J. L., DeVivo D. C., Rothman S. M. Mitochondrial morphology and intracellular calcium homeostasis in cytochrome oxidase-deficient human fibroblasts. Neurobiol. Dis. 3:1997;287-298.
22. Hayashi J.-I., Ohta S., Kagawa Y., Takai D., Miyabayashi S., Tada K., Fujushima H., Inui K., Okada S., Goto Y.-I., Nonaka I. Functional and morphological abnormalities of mitochondria in human cells containing mitochondrial DNA with pathogenic point mutations in tRNA genes. J. Biol. Chem. 269:1994;19060-19066.
23. Hoehn M. M., Yahr M. D. Parkinsonism: Onset, progression, and mortality. Neurology. 17:1967;427-442.
24. Kaido M., Fujimura H., Taniike M., Yoshikawa H., Toyooka K., Yorifuji S., Inui K., Okada S., Sparaco M., Yanagihara T. Focal cytochrome c oxidase deficiency in the brain and dorsal root ganglia in a case with mitochondrial encephalomyopathy (tRNA Ile4269 mutation): Histochemical, immunohistochemical, ultrastructural study. J. Neurol. Sci. 131:1995;170-176.
25. Kalichman M. W., Powell H. C., Mizisin A. P. Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy. Acta Neuropathol. 95:1998;47-56.
26. Kish S. J., Bergeron C., Rajput A., Dozic S., Mastrogiacomo F., Chang L. J., Wilson J. M., DiStefano L. M., Nobrega J. N. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 59:1992;113-114.
27. Kristal B. S., Dubinsky J. M. Mitochondrial permeability transition in the central nervous system: Induction by calcium cycling-dependent and -independent pathways. J. Neurochem. 69:1997;524-538.
28. Lach R., Grimes D., Benoit B., Minkiewicz-Janda A. Caudate nucleus pathology in Parkinson's disease: Ultrastructural and biochemical findings in biopsy material. Acta Neuropathol. 83:1992;352-360.
29. McKechnie N. M., King M., Lee W. R. Retinal pathology in the Kearns-Sayre syndrome. Br. J. Ophthalmol. 69:1985;63-75.
30. Miller S. W., Glasco S., Dykens J., Meredith M., Davis R. E. Creation and characterization of cybrid cell lines with defective cytochrome c oxidase activity from late-onset Alzheimer's disease. Soc. Neurosci. Abstr. 24:1998;1946.
31. Miller S. W., Trimmer P. A., Parker W. D. Jr., Davis R. E. Creation and characterization of mitochondrial DNA-depleted cell lines with "neuronal-like" properties. J. Neurochem. 67:1996;1897-1907.
32. Mitsumoto H., Aprille J. R., Wray S. H., Nemni R., Bradley W. G. Chronic progressive external ophthalmoplegia (CPEO): Clinical, morphological, and biochemical studies. Neurology. 33:1983;452-461.
33. Mizukawa K., Sora Y. H., Ogawa N. Ultrastructural changes of the substantia nigra, ventral tegmental area and striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-treated mice. Res. Commun. Chem. Pathol. Pharm. 67:1990;307-320.
34. Mutisya E. M., Bowling A. C., Beal M. F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63:1994;2179-2184.
35. Newell F. W., Palascik H. A. Mitochondrial disease and retinal pigmentary degeneration. Shimiza K., Oosterhuis J. Proceedings of the 23rd International Congress of Ophthalmology. 1979;615-617 Exerpta Medica International Congress, Amsterdam.
36. O'Gorman E., Piendl T., Muller M., Brdiczka D., Wallimann T. Mitochondrial intermembrane inclusion bodies: The common denominator between human mitochondrial myopathies and creatine depletion, due to impairment of cellular energetics. Mol. Cell. Biochem. 174:1997;283-289.
37. O'Kusky J. Methylmercury poisoning of the developing nervous system: Morphological changes in neuronal mitochondria. Acta Neuropathol. 61:1983;116-122.
38. Overly C. C., Rieff H. I., Hollenbeck P. J. Organelle motility and metabolism in axons vs dendrites of cultured hippocampal neurons. J. Cell Sci. 109:1996;971-980.
39. Parker W. D., Filley C. M., Parks J. K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology. 40:1990;1302-1303.
40. Parker W. D., Parks J. K., Filley C. M., Kleinschmidt-DeMasters B. K. Electron transport chain defects in Alzheimer's disease. Neurology. 44:1994;1090-1096.
41. Parker W. D. Jr., Swerdlow R. H. Mitochondrial dysfunction in idiopathic Parkinson disease. Am. J. Hum. Genet. 62:1998;758-762.
42. Parker W. D. J., Mahr N. J., Filley C. M., Parks J. K., Hughes D., Young D. A., Cullum C. M. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology. 44:1994;1086-1090.
43. Petit P. X., Goubern M., Diolez P., Susin S. A., Zamzami N., Kroemer G. Disruption of the outer mitochondrial membrane as a result of large amplitude swelling: The impact of irreversible permeability transition. FEBS Lett. 426:1998;111-116.
44. Pollanen M. S., Dickson D. W., Bergeron C. Pathology and biology of the Lewy body. J. Neuropathol. Exp. Neurol. 52:1993;183-191.
45. Rapisardi S. C., Warrington V. O. P., Wilson J. S. Effects of MPTP on the fine structure of neurons in substantia nigra of dogs. Brain Res. 512:1990;147-154.
46. Reers M., Smiley S. T., Mottola-Hartshorn C., Chen A., Lin M., Chen L. B. Mitochondrial membrane potential monitored by JC-1 dye. Attardi G. M., Chomyn A. Methods in Enzymology, Vol. 260, Mitochondrial Biogenesis and Genetics, Part A. 1995;407-417 Academic Press, New York.
47. Saraiva A. A., Borges M. M., Maderia M. D., Tavares M. A., Paula-Barbosa M. M. Mitochondrial abnormalities in cortical dendrites from patients with Alzheimer's disease. J. Submicrosc. Cytol. 17:1985;459-464.
48. Savage M. K., Reed D. J. Release of mitochondria glutathione and calcium by a cyclosporin A-sensitive mechanism occurs without large amplitude swelling. Arch. Biochem. Biophys. 315:1994;142-152.
49. Scalettar B. A., Abney J. R., Hackenbrock C. R. Dynamics, structure, and function are coupled in the mitochondrial matrix. Proc. Natl. Acad. Sci. USA. 88:1991;8057-8061.
50. Scarlett J. L., Murphy M. P. Release of apoptogenic proteins from the mitochondrial intermembrane space during the mitochondrial permeability transition. FEBS Lett. 418:1997;282-286.
51. Schapira A. H. V., Taanman J.-W., Tabrizi S. J., Seaton T., Cleeter M., Cooper J. M. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 44:1998;S89-S98.
52. Sekiya S., Tanaka M., Hayashi S., Oyanagi S. Light- and electron-microscopic studies of intracytoplasmic acidophilic granules in the human locus ceruleus and substantia nigra. Acta Neuropathol. 56:1982;78-80.
53. Sengers R. C. A., Stadhouders A. M., Trijbels J. M. F. Mitochondrial myopathies. Clinical, morphological and biochemical aspects. Eur. J. Ped. 141:1984;192-207.
54. Sheehan J. P., Swerdlow R. H., Miller S. W., Davis R. E., Parks J. K., Parker W. D., Tuttle J. B. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J. Neurosci. 17:1997;4612-4622.
55. Sheehan J. P., Swerdlow R. H., Parker W. D., Miller S. W., Davis R. E., Tuttle J. B. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J. Neurochem. 68:1997;1221-1233.
56. Smiley S. T., Reers M., Mottola-Hartshorn C., Lin M., Chen A., Smith T. W., Glenn J., Steele D., Chen L. B. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. USA. 88:1991;3671-3675.
57. Stadhouders A. M., Jap P. H. K., Winkler H.-P., Eppenberger H. M., Wallimann T. Mitochondrial creatine kinase: A major constituient of pathological inclusions seen in mitochondrial myopathies. Proc. Natl. Acad. Sci. USA. 91:1994;5089-5093.
58. Stadhouders A. M., Sengers R. C. A. Morphological observations in skeletal muscle from patients with a mitochondrial myopathy. J. Inherit. Metab. Dis. 10:1987;62-80.
59. Suomalainen A. Mitochondrial DNA and disease. Trends Mol. Med. 29:1997;235-246.
60. Swerdlow R. H., Parks J. K., Cassarino D. S., Maguire D. J., Maguire R. S., Bennett J. P. Jr., Davis R. E., Parker W. D. Jr. Cybrids in Alzheimer's disease. A cellular model of the disease. Neurology. 49:1997;918-925.
61. Swerdlow R. H., Parks J. K., Cassarino D. S., Trimmer P. A., Miller S. W., Maguire D. J., Sheehan J. P., Maguire R. S., Pattee G., Juel V. C., Phillips L. H., Tuttle J. B., Bennett J. P. Jr., Davis R. E., Parker W. D. Jr. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp. Neurol. 153:1998;135-142.
62. Swerdlow R. H., Parks J. K., Miller S. W., Davis I. J. N., Trimmer P. A., Tuttle J. B., Bennett J. P., Wooten G. F., Davis R. E., Parker W. D. Mitochondrial dysfunction in Parkinson's disease. Potential applications for cybrid modeling of the disease. Fisher A., Hanin I., Yoshida M. Advances in Behavior and Biology: Progress in Alzheimer's and Parkinson's Diseases. 1998;67-75 Plenum, New York.
63. Swerdlow R. H., Parks J. K., Miller S. W., Tuttle J. B., Trimmer P. A., Sheehan J. P., Bennett J. P. Jr., Davis R. E., Parker W. D. Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40:1996;663-671.
64. Tanaka J., Nakamure H., Honda S., Takada K., Kato S. Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey. Acta Neuropathol. 75:1988;370-376.
65. Tatton W. G., Chalmers-Redman R. M. Mitochondria in neurodegenerative apoptosis: An opportunity for therapy. Ann. Neurol. 44:1998;S134-141.
66. Trimmer P. A. PD cybrids contain inclusion bodies that share antigenic determinants with Lewy bodies. Soc. Neurosci. Abstr. 25:1999;1336.
67. Trimmer P. A., Swerdlow R. H., Parker W. D. Jr. Morphology of functionally impaired mitochondria in AD and PD cybrids is abnormal. Soc. Neurosci. Abstr. 24:1998;476.
68. Verwer R. W. H., Jansen K. A., Sluiter A. A., Terpstra J., Pool C. W., Swaab D. F. Reduced cytochrome oxidase activity in Alzheimer patients is not reflected in the immunoreactivity of its subunits, COX II and COX IV. Neurobiol. Aging Suppl. 1. 4S:1998;1135.
69. Wallace D. C., Shoffner J. M., Trounce I., Brown M. D., Ballinger S. W., Corral-Debrinski M., Horton T., Jun A. S., Lott M. T. Mitochondrial DNA mutations in human degenerative diseases and aging. Biochim. Biophys. Acta. 127:1995;141-151.
70. Zanssen S., Molnar M., Schroder J. M., Buse G. Multiple mitochondrial tRNALeu[UUR] mutations associated with infantile myopathy. Mol. Cell. Biochem. 174:1997;231-236.